BeyondSpring

BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. It operates through the PRC and U.S. geographical segments. The company was founded by Lan Huang and Lin Qing Jia in 2010 and is headquartered in New York, NY.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. It operates through the Plinabulin Pipeline and TPD Platform segments. The Plinabulin Pipeline segment focuses on the development of cancer therapies. The TPD Platform segment engages in the development of therapeutic agents and discover chemical entities. The company was founded by Lan Huang and Lin Qing Jia in 2010 and is headquartered in Florham Park, NJ.

Shares of BYSI stock are soaring on Wednesday after pharmaceutical firm BeyondSpring released positive data regarding its lung cancer drug. The post BYSI Stock: The Huge Cancer News Sending BeyondSpring Skyrocketing Today appeared first on InvestorPlace.

BYSI Stock: The Huge Cancer News Sending BeyondSpring Skyrocketing Today

BeyondSpring Inc. (NASDAQ: BYSI) shares are trading higher after the company announced results from its DUBLIN-3 trial of plinabulin in combination with docetaxel for non-small cell lung cancer, which showed the study met its primary endpoint and key secondary endpoints. Plinabulin, BeyondSpring's lead asset, is a selective immunomodulating microtubule-binding agent (SIMBA), which is a potent antigen-presenting cell (APC) inducer.

Why BeyondSpring's Stock Is Rallying Today

Shares of BeyondSpring Inc. more than tripled -- up 242% -- on heavy volume in premarket trading Wednesday, after the New York-headquartered biopharmaceutical company said a Phase 3 trial of its lung cancer treatment met the primary and key secondary endpoints. The stock, which closed at a record low last week, was on track to open at the highest price seen during regular-session hours since April 2018.

BeyondSpring stock more than triples after lung cancer treatment meets endpoints in Phase 3 trial

The stock price of Beyondspring Inc (NASDAQ: BYSI) increased by over 320% pre-market. This is why it happened.

BYSI Stock Price Increases Over 320% Pre-Market: Why It Happened

NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, announced today the positive topline data of DUBLIN-3 registrational trial in plinabulin in combination with docetaxel to treat 2nd and 3rd line NSCLC (EGFR wild type) compared to docetaxel alone (n=559). Plinabulin is a first-in-class, selective immunomodulating microtubule-binding agent (SIMBA), which is a potent antigen presenting cell (APC) inducer. The data released today showed that compared to docetaxel alone, the combination met the primary endpoint of increasing overall survival (mean OS, p = 0.03; OS log rank, p

BeyondSpring Announces Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment of 2nd/3rd Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Wild Type

BYSI has a November PDUFA for plinabulin in chemo-induced neutropenia. There are certain ways in which plinabulin and Spectrum's rolontis complement each other.

BeyondSpring's Plinabulin: Upcoming PDUFA And Positioning In The CIN Space

NEW YORK, July 14, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced the appointment of Brendan Delaney to its Board of Directors, effective immediately. Mr. Delaney brings his significant expertise in commercial oncology drug launches. BeyondSpring's lead developmental asset, plinabulin, is currently under Priority Review by the U.S. Food and Drug Administration (FDA) for the prevention of chemotherapy-induced neutropenia (CIN) with a U.S. Prescription Drug User Fee Act (PDUFA) action date of November 30, 2021. Mr. Delaney is expected to play an important role in the commercial launch planning for plinabulin and implementation, pending successful regulatory review.

BeyondSpring Strengthens Board with the Addition of Ex-Immunomedics and Constellation Commercial Head Brendan Delaney

NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management will participate in the William Blair Biotech Focus Conference being held virtually on July 14-15, 2021 and be available for 1x1 meetings. To participate in the conference, please contact conferences@williamblair.com to request a meeting.

BeyondSpring to Participate in the William Blair Biotech Focus Conference

NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced it will host a Research and Development (R&D) Day to discuss the development program for its novel immune agent, Plinabulin, in anti-cancer indications on Friday, June 25th, at 8:00 a.m. ET.

BeyondSpring to Host R&D Day to Discuss Novel Immune Agent Plinabulin's Development Program in Anti-cancer Indications

BeyondSpring Inc. (BYSI) CEO Dr. Lan Huang on Q1 2021 Results - Earnings Call Transcript

- NDA Filed by U.S. Food and Drug Administration (FDA) and given Priority Review for plinabulin plus G-CSF for the prevention of CIN. A PDUFA date of November 30, 2021 has been assigned by the FDA

BeyondSpring Announces First Quarter 2021 Financial Results and Provides a Corporate Update

NEW YORK, June 11, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management will host a conference call to report its financial results for the first quarter ended March 31, 2021 and provide an update on recent corporate events on June 16, 2021 at 8:30 AM Eastern Time.

BeyondSpring to Host First Quarter Financial Results and Corporate Update Conference Call on June 16, 2021

- Data further supports plinabulin's fast onset of action and CIN prevention benefit in week 1 following chemotherapy

BeyondSpring Announces Final Positive Data from the PROTECTIVE-1 Phase 3 CIN Program of Plinabulin as a Single Agent Compared to Pegfilgrastim at the American Society of Clinical Oncology (ASCO) Annual Meeting

NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the first patient had been dosed in the Phase 1b/2 investigator-initiated trial, studying the safety and tolerability of plinabulin, in triple combination therapy with both PD-1/PD-L1 antibody (mAb) and radiation therapy (RT). This triple combination is actively recruiting at The University of Texas MD Anderson Cancer Center, with Dr. Vivek Subbiah as principal investigator, in seven metastatic or locally advanced cancers, which include bladder cancer, melanoma, Merkel cell cancer, MSI-H cancers (of any histology), non-small cell lung cancer (NSCLC), renal cell cancer, and small cell lung cancer (SCLC).

BeyondSpring Announces First Patient Dosed in a Triple Combination Study with Plinabulin, PD-1/PD-L1 Inhibitor and Radiotherapy for the Reversal of Resistance to PD-1/PD-L1 Inhibitors in Patients with Advanced Solid Tumors

The FDA has accepted for review BeyondSpring Inc's (NASDAQ: BYSI) marketing application seeking approval for the use of plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) for the prevention of chemotherapy-induced neutropenia (CIN). Under the priority review, the target action date is set for November 30.

BeyondSpring's Plinabulin US Application for Chemo-Induced Neutropenia Under Review

- The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date for November 30, 2021

BeyondSpring Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia (CIN)

NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management is scheduled to present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 9:00 am ET and will be available for 1x1 meetings.

BeyondSpring to Present at the Jefferies Virtual Healthcare Conference on June 3, 2021

- Data from U.S. Phase 1 dose escalation investigator-initiated trial demonstrated favorable safety and tolerability.

BeyondSpring Presents Phase 1 Data on the Anti-Cancer Effect of Plinabulin in Combination with Checkpoint Inhibitors in SCLC at the American Society of Clinical Oncology (ASCO) Annual Meeting

AvroBio Inc

Fortress Biotech

Beyond Air Inc

Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.

4 Biotech Stocks Set to Outpace Q1 Earnings Estimates

NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that that CEO Dr. Lan Huang is scheduled to present at the Bank of America Securities 2021 Virtual Health Care Conference on Thursday, May 13, 2021 at 8:00 am ET and will be available for 1x1 meetings.

BeyondSpring to Present at the Bank of America Securities 2021 Health Care Conference on May 13, 2021

BeyondSpring Inc. (BYSI) CEO Dr. Lan Huang on Q4 2020 Results - Earnings Call Transcript

- NDAs filed in the U.S. and China in Mar. 2021 based on superior data from Phase 3 PROTECTIVE-2 trial of Breakthrough Therapy Designation regimen, plinabulin plus G-CSF vs. G-CSF alone in prevention of CIN

BeyondSpring Announces Fourth Quarter and Year End 2020 Financial Results and Provides a Corporate Update

- Four presentations to focus on the clinically meaningful endpoint improvement, including the reduction of febrile neutropenia and hospitalization, shown by plinabulin in the prevention of chemotherapy-induced neutropenia (CIN)

BeyondSpring Announces Five Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting

NEW YORK, April 27, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it will report its financial results for the quarter and year ended December 31, 2020 on Friday, April 30, 2021. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 8:30am Eastern Time.

BeyondSpring to Announce Fourth Quarter and Year End 2020 Financial Results and Host a Conference Call on Friday, April 30, 2021

Today, we take an in-depth look at BeyondSpring, a small cap concern focused on the development of immuno-oncology cancer therapies. In recent months, the company has addressed its current funding needs and continues to advance its pipeline.

News for BeyondSpring Stock (BYSI)